Increasing Prevalence of Chronic Diseases to Augment the Hospital Pharmaceuticals Market Growth

Hospital pharmaceuticals consist of medicines purchased for hospitals, healthcare centers to be administered to patients during hospitalization. Hospital pharmaceuticals include therapeutic and critical care drugs applied in infections, neurology, urology, cardiology, hematology, dermatology, respiratory system, musculoskeletal system, sensory organs, alimentary tract and metabolism, and other. The primary responsibility of hospital pharmacy is procurement, storage and selling of medications.

Market Dynamics:

Increasing incidence or prevalence of chronic diseases across the world, especially in the North America, is expected to propel the growth of the hospital pharmaceuticals market. For instance, chronic diseases such as diabetes, cancer, and heart disease, are the leading causes of death and disability in the United States, according to the Centers for Disease Control and Prevention (CDC). They are also leading drivers of the nation's $3.8 trillion in annual health care costs.

Moreover, the emergence of COVID-19 (SARS-CoV-2) is expected to augment the growth of the hospital pharmaceuticals market. For instance, in February 2021, Facing the challenge of a fast-paced and complex rollout of COVID-19 vaccines, Pennsylvania Hospital deployed radio frequency identification (RFID) technology to track the status of every vial that is removed from an ultra-freezer, then transported to the vaccination clinic, and sometimes returned to refrigeration, all while ensuring no vial expires before reaching a patient's arm.

Increasing demand for hospital pharmaceuticals and increasing spending on pharmaceuticals is also expected to fuel the growth of the hospital pharmaceuticals market. However,

Competitive Analysis:

Major players operating in the hospital pharmaceuticals market are Eli Lilly and Company, Merck & Co., Sanofi S.A., F. Hoffmann-La Roche Ltd, Johnson & Johnson, GlaxoSmithKline Plc., AstraZeneca Plc., Pfizer, Inc., Novartis AG, and Bayer AG.

Major players in the market are adopting various strategies, such as partnership, collaboration, product launch, etc., to enhance their market presence. For instance, in February 2021, Recce Pharma Ltd. formalized an agreement with Fiona Stanley Hospital for a Phase 1/2 clinical trial to assess the potential of RECCE 327’s new spray-on, broad-spectrum antibiotic for the treatment of topical burn wound infections.

In February 2021, Algernon Pharmaceuticals provided an update on the final data set of the Phase 2b part of the Phase 2b/3 COVID-19 Ifenprodil study.

In February 2021, Valeo Pharma and Ingenew Pharma announced that HespercoTM capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute's clinical trial, "The Hesperidin Coronavirus Study".

Comments

The Global Pressure Bandages Market Is Witnessing High Growth Owing To the Increasing Incidence of Surgical Processes in the World

Market Overview: During a medical emergency, a pressure bandage is used to apply pressure to an area of the body to control bleeding and swelling. There are a variety of types of pressure bandages that can be used for different purposes. The bandage is made up of several parts, including an air bladder, a pad, a closure bar, and an applicator. A pressure bandage can be applied to wounds at any location on the body. This type of dressing is useful in treating various conditions, including gunshot wounds. It can also be used for a temporary holding of a hernia. The bandage is usually vacuum-sealed, so it's easier to carry. Competitive Landscape: Major players operating in the global pressure bandages market include ConvaTec Group PLC., Cardinal Health, 3M, B. Braun Melsungen AG, Lohmann & Rauscher GmbH & Co. KG, Mölnlycke Health Care AB, Smith & Nephew plc., Paul Hartmann AG, and Essity (BSN medical GmbH). Key Market Drivers: Increasing developments by key pla...

Increasing Incidences of Infectious Diseases to Augment the Antibacterial Drugs Market Growth

Antibacterial drugs are widely used to treat and prevent infectious diseases and are categorized into seven major classes, such as β-Lactams, phenicols, macrolides, quinolones, sulfonamides, tetracyclines, and aminoglycosides, based on their molecular structure. Antibacterial drugs destroy or slow down the growth of bacteria. These medications are also used to treat urinary infections caused by S. aureus, E. coli, Streptococcus pyogenes, and other bacterial infections. They include a range of powerful drugs used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs. Antibacterial drugs play a major role in advanced healthcare, as they are widely used to treat infectious diseases, such as tuberculosis, malaria, typhoid, leprosy, hepatitis B, HIV/AIDS, and others. Thus, there is an increasing demand for antibacterial drugs worldwide.

Immuno-oncology: Combination Therapies and Emerging Targets

The study of and creation of therapies that use the immune system of the body to combat cancer are known as immuno-oncology. Our immune system, which is made up of a complex web of organs, cells, and molecules, guards us against external invaders like bacteria, fungus, and viruses that might infect us. The immune system is capable of locating and eliminating foreign objects as well as attacking aberrant cells. The immune system has the best chance of specifically destroying tumours without harming healthy tissue and having long-term memory that can stop cancer from coming back. The development of tumours can be permanently prevented or managed by a mechanism known as immunosurveillance, according to research in immuno-oncology conducted over the past 30 years. Recognition of tumour antigens is what gives the immune response its tumour specificity. The most well-established therapeutic class of IO drugs to date, immune checkpoint inhibitors have demonstrated significant effic...

Healthcare News

Search This Blog